Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) CAO Jonathan Wygant sold 5,032 shares of Veracyte stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $42.89, for a total value of $215,822.48. Following the transaction, the chief accounting officer now directly owns 42,313 shares in the company, valued at approximately $1,814,804.57. The trade was a 10.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Veracyte Stock Up 0.1 %
Shares of VCYT stock opened at $42.95 on Friday. The company’s fifty day simple moving average is $35.70 and its two-hundred day simple moving average is $29.03. Veracyte, Inc. has a 52 week low of $18.61 and a 52 week high of $44.16. The stock has a market cap of $3.33 billion, a P/E ratio of -286.33 and a beta of 1.67.
Veracyte (NASDAQ:VCYT – Get Free Report) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.16. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The company had revenue of $115.86 million for the quarter, compared to the consensus estimate of $109.81 million. During the same period in the previous year, the business earned ($0.03) earnings per share. The firm’s revenue for the quarter was up 28.6% on a year-over-year basis. On average, analysts anticipate that Veracyte, Inc. will post 0.32 EPS for the current fiscal year.
Institutional Trading of Veracyte
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the stock. UBS Group raised their target price on shares of Veracyte from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Wolfe Research initiated coverage on shares of Veracyte in a research report on Friday, November 15th. They set an “outperform” rating and a $50.00 price objective on the stock. Needham & Company LLC upped their target price on shares of Veracyte from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Leerink Partners raised their price target on Veracyte from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Morgan Stanley upped their price objective on Veracyte from $26.00 to $28.00 and gave the stock an “underweight” rating in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.25.
Read Our Latest Stock Analysis on Veracyte
About Veracyte
Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Veracyte
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- MarketBeat Week in Review – 11/25 – 11/29
- Stock Market Sectors: What Are They and How Many Are There?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.